VRD Consolidation Followed by Lenalidomide Maintenance versus Maintenance Alone in Transplant-Eligible Patients with NDMM

Conference Correspondent  - ASH Highlights

This randomized phase 3 trial of the European Myeloma Network sought to address the role of consolidation treatment for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The original randomization (R1) of this study (EMN02/HOVON95) compared intensification therapy using 4 cycles of bortezomib + melphalan + prednisone (VMP) versus high-dose melphalan (HDM) + single or double autologous stem-cell transplantation (ASCT), after induction with bortezomib + cyclophosphamide + dexamethasone; the R1 analysis results have been presented previously.

Reported here are the differential effects of a second randomization (R2) between consolidation treatment with 2 cycles of bortezomib + lenalidomide + dexamethasone (VRD) versus no consolidation, followed by lenalidomide 10 mg maintenance in both arms until disease progression or unacceptable toxicity. Consolidation treatment consisted of 2 28-day cycles of VRD (bortezomib 1.3 mg/m2 either intravenous or subcutaneous on days 1, 4, 8, and 11, + lenalidomide 25 mg orally on days 1-21, and dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11, and 12). Progression-free survival (PFS) from R1 and R2 were primary end points, but the study also included secondary end points of response and survival.

Randomized patients (n = 1212) for R1 were ≤65 years of age and had symptomatic multiple myeloma. Patients were stratified by International Staging System (ISS) stage. The VMP arm included 495 patients, whereas the HDM (followed by 1 or 2 ASCTs) arm included 702 patients. For R2, 894 patients were eligible, 878 of whom were included in R1. These patients were randomized to VRD consolidation (n = 451) or no consolidation (n = 427). At the time of R2, response status was equal between arms (ie, complete response or better [≥CR] in approximately 20%, very good partial response or better in 67%, and partial response or better in 92% of patients).

For the R2 population data analysis, median follow-up was 71.3 months (interquartile range, 63-80 months). At final analysis of R2 data, 512 events for PFS were reported. For the consolidation arm, 5-year PFS was 50% (95% confidence interval [CI], 45-55) versus 42% (95% CI, 37-46) without consolidation. Median PFS for those with and without consolidation was 59 months and 43 months, respectively, and PFS was longer for those in the VRD consolidation arm even when results were adjusted for R1 (hazard ratio [HR], 0.81; 95% CI, 0.68-0.96; P = .016). Revised ISS stage (HR, 2.05; 95% CI, 1.43-2.92) and presence of ampl1q (HR, 1.68; 95% CI, 1.38-2.06) were adverse prognostic factors at diagnosis. PFS was also determined across several predefined subgroups, and the benefit of consolidation was present in most of them, including revised ISS stage I to III, standard-risk cytogenetics, and both treatment arms of R1 (VMP or HDM treatment). The median duration of maintenance treatment was 33 months (range, 0-97+ months), and 32% of patients were still on treatment at 5 years after the initiation of lenalidomide.

Myeloma response was also greater after consolidation. CR (a secondary end point response) was achieved by 34% versus 18% of patients with and without consolidation, respectively (P <.001). Overall response ≥CR while on protocol was 59% versus 45% with and without consolidation, respectively (P <.001). Overall survival (OS) rate at 4 years from R2 (landmark estimate) was similar between arms (81%-82%), but at 6 years, the OS rate was 75% (95% CI, 71-79) in the consolidation arm versus 69% (95% CI, 64-73) without consolidation. VRD toxicity was acceptable and included a 5% incidence of grade 4 adverse events, which were mainly neutropenia (2%) and thrombocytopenia (2%).

When compared with maintenance alone, consolidation treatment with VRD followed by lenalidomide maintenance improves PFS and response in NDMM. Toxicity and secondary malignancy profiles are acceptable.


Reference

Abstract 550. ASH 2020. December 7, 2020. Consolidation Treatment with VRD Followed by Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95).

Related Items
Pevonedistat plus Azacitidine Improves Outcomes versus Azacitidine Monotherapy in High-Risk MDS
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Myelodysplastic Syndromes
Ruxolitinib in Graft-versus-Host Disease: Practice-Changing Results
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Graft-versus-Host-Disease
Step-Up Glofitamab Dosing Induces High Response Rates in Relapsed or Refractory Non-Hodgkin Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Clinical Trials, Lymphoma
ZUMA-12: Axicabtagene Ciloleucel Shows Substantial Benefit in High-Risk Large B-Cell Lymphoma
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, CAR T-Cell Therapy, Lymphoma
Momelotinib, a Novel JAK Inhibitor, Makes Inroads in Intermediate- or High-Risk Myelofibrosis
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Myelofibrosis, Novel Pharmaceuticals
Oral Vodobatinib Elicits Durable Responses in Heavily Pretreated Patients with Chronic Myeloid Leukemia
JHOP - February 2021 Vol 11, No 1 published on February 22, 2021 in ASH Highlights, Leukemia, Novel Pharmaceuticals
A Phase 2 Study of Isatuximab for Patients with Previously Treated AL Amyloidosis
Conference Correspondent  published on December 9, 2020 in ASH Highlights
A Dose-Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for RRMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
Phase 2 GRIFFIN Study Update: Daratumumab + Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Eligible NDMM
Conference Correspondent  published on December 9, 2020 in ASH Highlights
AMG 701, a Bispecific T-Cell Engager Molecule, in RRMM: A Phase 1 First-in-Human Study
Conference Correspondent  published on December 9, 2020 in ASH Highlights
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.